3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
15
Colorectal Neoplasms
15
Pancreatic Neoplasms
11
Colonic Neoplasms
9
Carcinoma, Hepatocellular
9
Esophageal Neoplasms
6
Rectal Neoplasms
5
Colorectal Neoplasms, Hereditary Nonpolyposis
4
Anus Neoplasms
4
Neoplasms
3
Gastrointestinal Stromal Tumors
3
Gastrointestinal Neoplasms
3
Gallbladder Neoplasms
3
Vulvar Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Intraepithelial Lesions
2
Peritoneal Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
Cholangiocarcinoma
2
Bile Duct Neoplasms
2
Acquired Immunodeficiency Syndrome
2
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Recurrence
1
Pseudomyxoma Peritonei
1
Prostatic Neoplasms
1
Papillomavirus Infections
1
Interventions
pembrolizumab
12
Nivolumab
6
Cyclophosphamide
6
fludarabine
5
Ipilimumab
4
amatuximab
3
Cisplatin
3
tislelizumab
2
spartalizumab
2
fludarabine phosphate
2
budigalimab
2
belinostat
2
Plicamycin
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fluorouracil
2
Cytoreduction Surgical Procedures
2
venetoclax
1
tocilizumab
1
talazoparib
1
sotorasib
1
rovalpituzumab tesirine
1
obinutuzumab
1
niraparib
1
naptumomab estafenatox
1
milademetan
1
irinotecan sucrosofate
1
epacadostat
1
enzalutamide
1
durvalumab
1
defactinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Observation
×
Gastrointestinal
×
Clear all
NCT02073500
2021-07-28
PSM
Oslo University Hospital
Recruiting
300 enrolled